HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lawsuit Will Question Supplement Exclusion From Lycopene/Cancer Claims

This article was originally published in The Tan Sheet

Executive Summary

American Longevity will file a lawsuit against FDA no later than Dec. 9 in response to the agency's denial of qualified health claims tying lycopene-containing dietary supplements to cancer risk reduction

You may also be interested in...



Emord Extends Effort To Liberalize QHCs With Selenium, Antioxidant Petitions

Attorney Jonathan Emord continues his effort to force FDA to allow more expansive qualified health claims for nutritional supplements with two petitions relating to the capability of selenium and antioxidant vitamins to reduce the risk of site-specific cancers

Heart Benefits Included In Future Research For Tomatoes, Lycopene – Heinz

Lack of validated biomarkers for prostate cancer was one of the "big problems" for H.J. Heinz during the submission process for its qualified health claim for lycopene in tomato products, according to its Global Nutrition director

QHC Letters Preview Final Guidance; “Read Them,” Stresses Schneeman

FDA's letters of enforcement discretion offer industry a rough draft of the agency's upcoming final guidance on health claim substantiation, according to the Center for Food Safety & Nutrition's Barbara Schneeman, PhD

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS126683

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel